Abacavir

證據等級: L5

預測適應症: 3 個

Abacavir: From HIV-1 Infection to Simian Immunodeficiency Virus Infection

One-Sentence Summary

Abacavir (ABC) is a nucleoside reverse transcriptase inhibitor (NRTI) used as part of combination antiretroviral therapy for HIV-1 infection in humans. The TxGNN model predicts it may be effective against Simian Immunodeficiency Virus (SIV) Infection — a primate lentiviral disease mechanistically related to HIV-1 — with no registered clinical trials and 1 preclinical publication currently available to support this direction.

Quick Overview

Item	Content
Original Indication	HIV-1 infection (combination antiretroviral therapy; inferred from clinical context — not yet registered in the Philippines)
Predicted New Indication	Simian Immunodeficiency Virus (SIV) Infection
TxGNN Prediction Score	99.79%
Evidence Level	L4
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacological information, Abacavir is a carbocyclic synthetic nucleoside analogue whose intracellular active metabolite — carbovir triphosphate (CBV-TP) — competitively inhibits HIV-1 reverse transcriptase and terminates viral DNA chain elongation, blocking viral replication.

SIV and HIV-1 are both primate lentiviruses (family Retroviridae) that share the same RNA-dependent DNA polymerase (reverse transcriptase) replication mechanism. The amino acid sequence homology between SIV RT and HIV-1 RT is approximately 80%, suggesting that CBV-TP could competitively occupy the SIV RT catalytic site and terminate proviral DNA synthesis in an analogous manner. In vitro susceptibility data further supports cross-species applicability of NRTIs at this homology level. This is the most likely basis for TxGNN’s high prediction score.

It should be noted that SIV infection primarily affects non-human primates and is not a direct human clinical disease. The practical relevance of this prediction therefore lies more in supporting primate HIV research models than in direct clinical repurposing. If the research objective is a human indication, a closer analogue would be HIV-2 — also covered by the same preclinical study identified below.

Clinical Trial Evidence

Currently no related clinical trials registered for Abacavir in simian immunodeficiency virus infection.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15040537	2004	In vitro / Preclinical susceptibility assay	Antiviral Therapy	Evaluated 16 approved antiretrovirals (including Abacavir) against HIV-2 (ROD, EHO), SIV (mac251, B670) and SHIV strains; provides comparative susceptibility data across primate lentivirus species with implications for treatment and post-exposure prophylaxis design

Philippines Market Information

Abacavir currently has no product registrations with the Philippine Food and Drug Administration (FDA-PH). There are no active licenses, approved indications, or marketed formulations on record.

Safety Considerations

Please refer to the package insert for safety information.

Note: Philippines FDA-registered package insert data (warnings, contraindications) was not available in this evidence pack (Data Gap: DG001). Drug interaction data was also not retrieved. These gaps must be resolved before any clinical decision-making can proceed.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction is mechanistically coherent — SIV and HIV-1 share ~80% RT sequence homology, making Abacavir’s NRTI mechanism theoretically applicable — but the predicted indication is a non-human primate disease with no direct human clinical target, Abacavir is not registered in the Philippines, and critical safety data is absent from this pack.

To proceed, the following is needed:

Clarify research objective: Determine whether the goal is (a) supporting non-human primate HIV research models, (b) exploring cross-species antiretroviral activity for veterinary use, or (c) identifying a related human indication (e.g., HIV-2, which shares the same preclinical evidence)
Retrieve MOA data: Query DrugBank API for Abacavir mechanism of action, target binding data, and resistance profile (Data Gap: DG002)
Retrieve safety data: Download and parse the Philippines FDA (or FDA-approved) package insert for warnings, contraindications, and known drug interactions (Data Gap: DG001)
Expand literature search: Conduct a structured review of Abacavir in vivo activity against SIV strains — current evidence is limited to a single in vitro susceptibility assay
Consider re-ranking for human indication: If human clinical repurposing is the goal, evaluate whether Rank 2 (feline AIDS) or other TxGNN predictions with more direct human disease biology warrant promotion to primary candidate
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.